Literature DB >> 14557483

Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas.

A-C Gérard1, C Daumerie, C Mestdagh, S Gohy, C De Burbure, S Costagliola, F Miot, M-C Nollevaux, J-F Denef, J Rahier, B Franc, J J M De Vijlder, I M Colin, M-C Many.   

Abstract

Progress in biotechnology has provided useful tools for tracing proteins involved in thyroid hormone synthesis in vivo. Mono- or polyclonal antibodies are now available to detect on histological sections the Na(+)/I(-) symporter (NIS) at the basolateral pole of the cell, the putative iodide channel (pendrin) at the apical plasma membrane, thyroperoxidase (TPO), and members of the NADPH-oxidase family, thyroid oxidase 1 and 2 (ThOXs), part of the H(2)O(2)-generating system. The aim of this study was to correlate thyroglobulin (Tg) iodination with the presence of these proteins. Tg, T(4)-containing Tg, NIS, pendrin, TPO, ThOXs, and TSH receptor (TSHr) were detected by immunohistochemistry on tissue sections of normal thyroids and various benign and malignant thyroid disorders. Tg was present in all cases. T(4)-containing Tg was found in the adenomas, except in Hurthle cell adenomas. It was never detected in carcinomas. NIS was reduced in all types of carcinomas, whereas it was detected in noncancerous tissues. Pendrin was not expressed in carcinomas, except in follicular carcinomas, where weak staining persisted. TPO expression was present in insular, follicular carcinomas and in follicular variants of papillary carcinomas, but in a reduced percentage of cells. It was below the level of detection in papillary carcinomas. The H(2)O(2)-generating system, ThOXs, was found in all carcinomas and was even increased in papillary carcinomas. Its staining was apical in normal thyroids, whereas it was cytoplasmic in carcinomas. The TSHr was expressed in all cases, but the intensity of the staining was decreased in insular carcinomas. In conclusion, our work shows that all types of carcinomas lose the capacity to synthesize T(4)-rich, iodinated Tg. In follicular carcinomas, this might be due to a defect in iodide transport at the basolateral pole of the cell. In papillary carcinomas, this defect seems to be coupled to an altered apical transport of iodide and probably TPO activity. The TSHr persists in virtually all cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557483     DOI: 10.1210/jc.2003-030586

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Recent insights into the cell biology of thyroid angiofollicular units.

Authors:  Ides M Colin; Jean-François Denef; Benoit Lengelé; Marie-Christine Many; Anne-Catherine Gérard
Journal:  Endocr Rev       Date:  2013-01-24       Impact factor: 19.871

2.  Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors.

Authors:  Svetlana Savin; Dubravka Cvejic; Tijana Isic; Ivana Petrovic; Ivan Paunovic; Svetislav Tatic; Marija Havelka
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

3.  Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.

Authors:  S J Lee; K-C Choi; J P Han; Y-E Park; M G Choi
Journal:  J Endocrinol Invest       Date:  2007-01       Impact factor: 4.256

Review 4.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

Review 5.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

6.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

7.  Association between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies.

Authors:  Rui Zhang; Huanjun Wang; Junyu Zhao; Jinming Yao; Hongxia Shang; Huangao Zhu; Lin Liao; Jianjun Dong
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake.

Authors:  C A Fernández; M Puig-Domingo; F Lomeña; M Estorch; V Camacho Martí; A L Bittini; M Marazuela; J Santamaría; J Castro; P Martínez de Icaya; I Moraga; T Martín; A Megía; M Porta; D Mauricio; I Halperin
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

9.  Deletion of the RNaseIII enzyme dicer in thyroid follicular cells causes hypothyroidism with signs of neoplastic alterations.

Authors:  Wendy Rodriguez; Ling Jin; Véronique Janssens; Christophe Pierreux; Anne-Christine Hick; Eneko Urizar; Sabine Costagliola
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

Review 10.  Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.

Authors:  X Cai; R Wang; J Tan; Z Meng; N Li
Journal:  Clin Transl Oncol       Date:  2021-06-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.